{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:55:21Z","timestamp":1768622121888,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s12325-008-0071-5","type":"journal-article","created":{"date-parts":[[2008,6,22]],"date-time":"2008-06-22T21:37:53Z","timestamp":1214170673000},"page":"552-566","source":"Crossref","is-referenced-by-count":4,"title":["Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study"],"prefix":"10.1007","volume":"25","author":[{"given":"Ozlen","family":"Atug","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Giral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Kalayci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enver","family":"Dolar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahri","family":"Isitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oya","family":"Ovunc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Ozgur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Soykan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkay","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selahattin","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necati","family":"Yenice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,6,23]]},"reference":[{"key":"71_CR1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000200911","volume":"51","author":"S.J. Spechler","year":"1992","unstructured":"Spechler SJ. Epidemiology and natural history of gastro-esophageal reflux disease. Digestion. 1992;51(suppl):24\u201349.","journal-title":"Digestion"},{"key":"71_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mcna.2004.08.006","volume":"89","author":"R.C. Orlando","year":"2005","unstructured":"Orlando RC. Pathogenesis of reflux esophagitis and Barrett\u2019s esophagus. Med Clin North Am. 2005;89:219\u2013241.","journal-title":"Med Clin North Am."},{"key":"71_CR3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.38.5.649","volume":"38","author":"R.H. Holloway","year":"1996","unstructured":"Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut. 1996;38:649\u2013654.","journal-title":"Gut."},{"key":"71_CR4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/00365528609011128","volume":"21","author":"K.E. Johansson","year":"1986","unstructured":"Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1986;21:837\u2013847.","journal-title":"Scand J Gastroenterol."},{"key":"71_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.03235.x","volume":"25","author":"P.O. Katz","year":"2007","unstructured":"Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2007;25:617\u2013628.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR6","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","volume":"112","author":"N. Chiba","year":"1997","unstructured":"Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade 2 to 4 gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798\u20131810.","journal-title":"Gastroenterology."},{"key":"71_CR7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s002280000206","volume":"56","author":"M. Hassan-Alin","year":"2000","unstructured":"Hassan-Alin M, Andersson T, Bredberg E, R\u00f6hss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol. 2000;56:665\u2013670.","journal-title":"Eur J Clin Pharmacol."},{"key":"71_CR8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2036.2000.00813.x","volume":"14","author":"T. Lind","year":"2000","unstructured":"Lind T, Rydberg L, Kyleb\u00e4ck A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:861\u2013867.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR9","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","volume":"98","author":"P. Miner Jr","year":"2003","unstructured":"Miner PJr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98:2616\u20132620.","journal-title":"Am J Gastroenterol."},{"key":"71_CR10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-004-0804-6","volume":"60","author":"K. R\u00f6hss","year":"2004","unstructured":"R\u00f6hss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg. in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60:531\u2013539.","journal-title":"Eur J Clin Pharmacol."},{"key":"71_CR11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","volume":"14","author":"P. Kahrilas","year":"2000","unstructured":"Kahrilas P, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther. 2000;14:1249\u20131258.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","volume":"96","author":"J.E. Richter","year":"2001","unstructured":"Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656\u2013665.","journal-title":"Am J Gastroenterol."},{"key":"71_CR13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","volume":"97","author":"D.O. Castell","year":"2002","unstructured":"Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575\u2013583.","journal-title":"Am J Gastroenterol."},{"key":"71_CR14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","volume":"21","author":"J. Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005;21:739\u2013746.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","volume":"96","author":"D.A. Johnson","year":"2001","unstructured":"Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintenance of healing of erosive esophagitis and control of GERD symptoms. Am J Gastroenterol. 2001;96:27\u201334.","journal-title":"Am J Gastroenterol."},{"key":"71_CR16","first-page":"926","volume":"15","author":"N.B. Vakil","year":"2001","unstructured":"Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis. A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:926\u2013935.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","volume":"14","author":"N.J. Talley","year":"2002","unstructured":"Talley NJ, Venables T, Green J, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative GERD: a placebo controlled trial of \u2018on-demand\u2019 therapy for 6 months. Eur J Gastroenterol Hepatol. 2002;14:857\u2013863.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"71_CR18","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","volume":"4","author":"I.M. Gralnek","year":"2006","unstructured":"Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452\u20131458.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"71_CR19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2036.2006.03074.x","volume":"24","author":"S.J. Edwards","year":"2006","unstructured":"Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis \u2014 a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther. 2006;24:743\u2013750.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","volume":"45","author":"L.R. Lundell","year":"1999","unstructured":"Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172\u2013180.","journal-title":"Gut."},{"key":"71_CR21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","volume":"41","author":"R. Fass","year":"2007","unstructured":"Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131\u2013137.","journal-title":"J Clin Gastroenterol."},{"key":"71_CR22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00001574-200107000-00011","volume":"17","author":"A. Rai","year":"2001","unstructured":"Rai A, Orlando RC. Gastroesophageal reflux disease. Curr Opin Gastroenterol. 2001;17:359\u2013365.","journal-title":"Curr Opin Gastroenterol."},{"key":"71_CR23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","volume":"12","author":"A.B. Thomson","year":"1998","unstructured":"Thomson AB, Chiba N, Armstrong D, Tougas G, Hunt RH. The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Can J Gastroenterol. 1998;12:551\u2013556.","journal-title":"Can J Gastroenterol."},{"issue":"B","key":"71_CR24","first-page":"66B","volume":"1","author":"N. Chiba","year":"1997","unstructured":"Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systemic overview. Can J Gastroenterol. 1997;1(suppl B):66B\u201373B.","journal-title":"Can J Gastroenterol."},{"key":"71_CR25","doi-asserted-by":"crossref","first-page":"A439","DOI":"10.1016\/S0016-5085(08)82176-2","volume":"120","author":"D.A. Johnson","year":"2001","unstructured":"Johnson DA, Vakil NB, Hwang C, Levine JG. Absence of symptoms in erosive esophagitis (EE) in patients treated with esomeprazole is a highly reliable indicator of healing. Gastroenterology. 2001;120:A439.","journal-title":"Gastroenterology."},{"issue":"III","key":"71_CR26","first-page":"A166","volume":"50","author":"D.A. Johnson","year":"2002","unstructured":"Johnson DA, Vakil NB, Richter JE, Zuckerman S, Levine JG, Skammer W. Sustained heartburn resolution during the first 4 weeks of PPI therapy predicts subsequent healing in GERD patients with erosive esophagitis. Gut. 2002;50(suppl III):A166.","journal-title":"Gut."},{"key":"71_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MEG.0b013e32801055d5","volume":"19","author":"K.L. Goh","year":"2007","unstructured":"Goh KL, Benamouzig R, Sander P, Schwan T. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial \u2014 the EMANCIPATE study. Eur J Gastroenterol Hepatol. 2007;19:205\u2013211.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"71_CR28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2036.2005.02643.x","volume":"22","author":"J. Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther. 2005;22:803\u2013811.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","volume":"4","author":"K.R. Devault","year":"2006","unstructured":"Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized sixmonth comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852\u2013859.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"71_CR30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2036.2003.01464.x","volume":"17","author":"K. Lauritsen","year":"2003","unstructured":"Lauritsen K, Devi\u00e8re J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther. 2003;17:333\u2013341.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR31","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1572-0241.1998.00523.x","volume":"93","author":"J.E. Richter","year":"1998","unstructured":"Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol. 1998;93:1800\u20131802.","journal-title":"Am J Gastroenterol."},{"key":"71_CR32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/bmj.326.7392.737","volume":"326","author":"A. Raghunath","year":"2003","unstructured":"Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326:737.","journal-title":"BMJ."},{"key":"71_CR33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0163-4453(98)80169-2","volume":"37","author":"D. Us","year":"1998","unstructured":"Us D, Has\u00e7elik G. Seroprevalance of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect. 1998;37:148\u2013150.","journal-title":"J Infect."},{"key":"71_CR34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00042737-200106000-00026","volume":"13","author":"L. Lundell","year":"2001","unstructured":"Lundell L. Gastro-oesophageal reflux disease and Helicobacter pylori or gastrooesophageal reflux disease from Helicobacter pylori? Eur J Gastroenterol Hepatol. 2001;13:23\u201327.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"71_CR35","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/gut.36.4.539","volume":"36","author":"E.F. Verd\u00fa","year":"1995","unstructured":"Verd\u00fa EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut. 1995;36:539\u2013543.","journal-title":"Gut."},{"key":"71_CR36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2036.1999.00531.x","volume":"13","author":"M.A. Herwaarden Van","year":"1999","unstructured":"Van Herwaarden MA, Samsom M, Van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther. 1999;13:731\u2013740.","journal-title":"Aliment Pharmacol Ther."},{"key":"71_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0016-5085(99)70544-5","volume":"117","author":"G. Holtmann","year":"1999","unstructured":"Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology. 1999;117:11\u201316.","journal-title":"Gastroenterology."},{"key":"71_CR38","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/j.1572-0241.2000.02454.x","volume":"95","author":"N. Vakil","year":"2000","unstructured":"Vakil N, Kahrilas P, Magner D, Skammer W, Levine J. Does baseline Hp status impact erosive oesophagitis (EE) healing rates? Am J Gastroenterol. 2000;95:2438\u20132439.","journal-title":"Am J Gastroenterol."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0071-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-008-0071-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-008-0071-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:55:51Z","timestamp":1559447751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-008-0071-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s12325-008-0071-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}